Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia

被引：7

作者：

Kucine, Nicole ^{[1
]}

Bergmann, Shayla ^{[2
]}

Krichevsky, Spencer ^{[3
]}

Jones, Devin ^{[4
]}

Rytting, Michael ^{[5
]}

Jain, Juhi ^{[6
]}

Bennett, Carolyn M. ^{[6
]}

Resar, Linda M. S. ^{[7
,8
,9
]}

Mascarenhas, John ^{[4
]}

Verstovsek, Srdan ^{[10
]}

Hoffman, Ronald ^{[4
]}

机构：

[1] Weill Cornell Med, Dept Pediat, New York, NY USA

[2] Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA

[3] Weill Cornell Med, Richard T Silver Myeloproliferat Neoplasm Ctr, New York, NY USA

[4] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, New York, NY 10029 USA

[5] Lakeshore Hlth Partners, Holland, MI USA

[6] Emory Univ, Sch Med, Dept Pediat, Childrens Healthcare Atlanta,Aflac Canc & Blood D, Atlanta, GA USA

[7] Johns Hopkins Univ SOM, Dept Med, Div Hematol, Baltimore, MD USA

[8] Johns Hopkins Univ SOM, Dept Oncol, Div Hematol, Baltimore, MD USA

[9] Johns Hopkins Univ SOM, Dept Pathol, Div Hematol, Baltimore, MD USA

[10] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

PEDIATRIC BLOOD & CANCER | 2021年 / 68卷 / 03期

关键词：

essential thrombocytosis; interferon; myeloproliferative neoplasm; polycythemia vera;

D O I：

10.1002/pbc.28888

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Myeloproliferative neoplasms (MPN) are rare disorders in young patients, and because of this, standardized treatment recommendations are not available. Pediatric patients are more frequently treated with hydroxyurea than interferon, yet there are no data suggesting this is the best practice. Current treatment guidelines for adults suggest using interferon as upfront therapy in young patients. We reviewed the cases of 13 young patients with polycythemia vera or essential thrombocythemia, who were treated with interferon. Extreme thrombocytosis was well controlled and the medication was tolerated by many. Our work shows the need for prospective studies evaluating interferon in our youngest patients with MPN.

引用

页数：4

共 50 条

[1] Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
Quintas-Cardama, Alfonso
Abdel-Wahab, Omar
Manshouri, Taghi
Kilpivaara, Outi
Cortes, Jorge
Roupie, Anne-Laure
Zhang, Su-Jiang
Harris, David
Estrov, Zeev
Kantarjian, Hagop
Levine, Ross L.
Verstovsek, Srdan
[J]. BLOOD, 2013, 122 (06) : 893 - 901
[2] Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera
Sokolova, M. A.
Turkina, A. G.
Melikian, A. L.
Sudarikov, A. B.
Treglazova, S. A.
Shukhov, O. A.
Gemdzhian, E. G.
Abdullaev, A. O.
Kovrigina, A. M.
Misyurin, A. V.
Pliskunova, Yu. V.
Ivanova, V. L.
Moiseeva, T. N.
[J]. TERAPEVTICHESKII ARKHIV, 2016, 88 (12): : 69 - 77
[3] Pegylated Interferon Alpha-2b in Patients With Polycythemia Vera and Essential Thrombocythemia in the Real World
Sun, Yingxin
Cai, Yifeng
Cen, Jiannong
Zhu, Mingqing
Pan, Jinlan
Wang, Qian
Wu, Depei
Chen, Suning
[J]. FRONTIERS IN ONCOLOGY, 2021, 11
[4] Interferon-α therapy in polycythemia vera and essential thrombocythemia
Elliott, MA
Tefferi, A
[J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1997, 23 (05): : 463 - 472
[5] Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
Silver, Richard T.
Kiladjian, Jean-Jacques
Hasselbalch, Hans Carl
[J]. EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (01) : 49 - 58
[6] Pegylated interferon alfa-2a is effective and decreases LDH levels in patients with essential thrombocythemia and polycythemia vera
Ekinci, O.
[J]. LEUKEMIA RESEARCH, 2019, 85 : S27 - S27
[7] Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Yacoub, Abdulraheem
Mascarenhas, John
Kosiorek, Heidi
Prchal, Josef T.
Berenzon, Dmitry
Baer, Maria R.
Ritchie, Ellen
Silver, Richard T.
Kessler, Craig
Winton, Elliott
Finazzi, Maria Chiara
Rambaldi, Alessandro
Vannucchi, Alessandro M.
Leibowitz, David
Rondelli, Damiano
Arcasoy, Murat O.
Catchatourian, Rosalind
Vadakara, Joseph
Rosti, Vittorio
Hexner, Elizabeth
Kremyanskaya, Marina
Sandy, Lonette
Tripodi, Joseph
Najfeld, Vesna
Farnoud, Noushin
Papaemmanuil, Elli
Salama, Mohamed
Singer-Weinberg, Rona
Rampal, Raajit
Goldberg, Judith D.
Barbui, Tiziano
Mesa, Ruben
Dueck, Amylou C.
Hoffman, Ronald
[J]. BLOOD, 2019, 134 (18) : 1498 - 1509
[8] \ Erythromelalgia in patients with essential thrombocythemia and polycythemia vera
Hou, Jennifer L.
Onajin, Oluwakemi
Gangat, Naseema
Davis, Mark D. P.
Wolanskyj, Alexandra P.
[J]. LEUKEMIA & LYMPHOMA, 2017, 58 (03) : 715 - 717
[9] Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)
Masarova, Lucia
Yin, C. Cameron
Cortes, Jorge E.
Konopleva, Marina
Borthakur, Gautam
Newberry, Kate J.
Kantarjian, Hagop M.
Bueso-Ramos, Carlos E.
Verstovsek, Srdan
[J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2017, 6
[10] Experience with oral interferon-alpha in patients with essential thrombocythemia and polycythemia vera
Ouintas-Cardama, Alfonso
Verstovsek, Srdan
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (09) : 859 - 859

← 1 2 3 4 5 →